Cointime

Santhera Pharmaceuticals

company

About

Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.

  • 51 - 100

Highlights

Total Funding Amount
$11.14M €16M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$11.14M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Sep 1, 2004
Number Of Employee
51 - 100
Operating Status
Active

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$11.14M €16M
Santhera Pharmaceuticals has raised a total of $11.14M €16M in funding over 2 rounds. Their latest funding was raised on Oct 30, 2013 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 30, 2013 Post-IPO Equity $11.14M 1 YA Global Master SPV — Detail
Dec 20, 2005 Series B €16M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Santhera Pharmaceuticals is funded by 2 investors. YA Global Master SPV and Varuma are the most recent investors.
Investor Name Lead Investor Funding Round
YA Global Master SPV Yes Post-IPO Equity
Varuma — Series B
Cointime
İçerikler
Şirket.